KIORA PHARMACEUTICALS

Company snapshot

Kiora Pharmaceuticals, Inc. (Kiora) is a clinical stage biotech company focusing on novel therapeutics for the treatment of retinal diseases. Publicly traded on the NASDAQ under KPRX, our mission is to help patients improve and/or restore vision.

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 US patent(s) indexed to this assignee profile.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for KIORA PHARMACEUTICALS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for KIORA PHARMACEUTICALS.

1. Jun 8, 2026 Clinical update

   OBG PED-001 — Phase 2

2. Jun 8, 2026 Clinical update

   100 μg KIO-301 — Phase 2

3. Jun 5, 2026 Clinical update

   KIO-104 — Phase 2

4. May 26, 2026 Clinical update

   KIO-101 — Phase 2

5. May 23, 2026 Clinical update

   KIO-301 — Phase 2

View all clinical trial activity →

• What is KIORA PHARMACEUTICALS?

  Kiora Pharmaceuticals is a pharma organization headquartered in Encinitas, USA. It trades on NYSE under ticker KPRX. Primary therapeutic focus areas include Retinitis Pigmentosa, Dry Eye Disease, Macular Edema, Persistent Corneal Epithelial Defect. NovaPharmaNews links 5 clinical

• Is KIORA PHARMACEUTICALS publicly traded?

  Yes. KIORA PHARMACEUTICALS is listed with ticker KPRX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does KIORA PHARMACEUTICALS develop or market?

  We link 4 drug profile(s) where KIORA PHARMACEUTICALS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/kiora-pharmaceuticals-inc#company-drugs.

• What are the latest developments for KIORA PHARMACEUTICALS?

  In the last 12 months our linked public records show 5 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does KIORA PHARMACEUTICALS focus on?

  KIORA PHARMACEUTICALS focuses on Retinitis Pigmentosa, Dry Eye Disease, Macular Edema based on our analysis of their pipeline programs and drug development activities.